Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart ...

a developmental stage medical device company, focuses on the development and commercialization of ablation ... including atrial fibrillation, atrial flutter, and ventricular tachycardia.

Field Medical secures major funding to reimagine life-saving cardiac care through next-gen ablation therapies.

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of $40 million ...

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of ...

Catheter Ablation Devices for Atrial Fibrillation Market 2035, Driven by advanced devices, better clinical outcomes, and rising regulatory approvals.